GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Some studies have also identified potential associations with dementia. The $1.7 million study, funded by GlaxoSmithKline (GSK), which makes Shingrix, will allow Harris to emulate two target trials ...

Based on the shingles incidence rate from the placebo arm North American cohort of ZOSTER-006, a Phase 3 trial of Shingrix, 10 of the 876 participants in the Phase 2 trial should have been diagnosed ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

Positive data from 876-patient head-to-head trial versus Shingrix ® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity -- Updated data will ...